Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPH 65

Next Previous
Drug Profile

IPH 65

Alternative Names: CD20-NKCE-IL2v; IPH-65; IPH-6501; Tetra-specific ANKET; Tetra-specific NK cell engaging antibody - Innate Pharma

Latest Information Update: 22 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innate Pharma
  • Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; Interleukin 2 replacements; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 14 Apr 2026 Innate Pharma terminates a phase I/II trial in Non-Hodgkin Lymphoma (Late-stage disease, Second-line therapy or greater) in the USA, Australia and France due to company's strategic priorisation of its pipeline(NCT06088654)
  • 13 Jun 2025 Pharmacodynamics data from the preclinical trial in Non-Hodgkin's lymphoma released by Innate Pharma
  • 13 Jun 2024 Pharmacodynamics data from a preclinical trial in Non-Hodgkin's lymphoma presented at the 29th Congress of the European Haematology Association (EHA-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top